<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Voretigene neparvovec: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Voretigene neparvovec: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Voretigene neparvovec: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="116218" href="/d/html/116218.html" rel="external">see "Voretigene neparvovec: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="117666" href="/d/html/117666.html" rel="external">see "Voretigene neparvovec: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50929308"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Luxturna</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56774950"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Luxturna</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50875200"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gene Therapy, Adeno-Associated Virus</li></ul></div>
<div class="block doa drugH1Div" id="F51062979"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ef90779-d7fd-4e1c-bb43-cdcab77ceba7">Retinal dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retinal dystrophy:</b> Subretinal: 1.5 x 10<sup>11</sup> vector genomes in a total volume of 0.3 mL injected into each eye on separate days within a close interval (no fewer than 6 days apart).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Concomitant medications:</i> Systemic oral corticosteroids equivalent to prednisone 1 mg/kg/day (maximum: 40 mg/day) for a total of 7 days (starting 3 days before administration of voretigene neparvovec to the first eye), and followed by tapering the dose during the following 10 days. The same corticosteroid dosing regimen applies for administration to the second eye. If the corticosteroid taper to the first eye is not complete 3 days before planned administration to the second eye, the corticosteroid regimen for the second eye replaces the taper for the first eye.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F51063434"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, no adjustment expected due to minimal systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F51063435"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, no adjustment expected due to minimal systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F51062981"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51062980"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="117666" href="/d/html/117666.html" rel="external">see "Voretigene neparvovec: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Beginning 3 days before administration of first dose in the first eye, initiate systemic oral corticosteroids equivalent to prednisone 1 mg/kg/day (maximum daily dose: 40 mg<b>/day</b>) and continue for a total of 7 days, then taper corticosteroid dose during the following 10 days. The same corticosteroid dosing regimen applies for administration to the second eye. If the corticosteroid taper to the first eye is not complete 3 days before planned administration to the second eye, the corticosteroid regimen for the second eye replaces the taper for the first eye regimen.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ef90779-d7fd-4e1c-bb43-cdcab77ceba7">Retinal dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retinal dystrophy:</b> Children and Adolescents: Ophthalmic: Subretinal injection: 1.5 x 10<sup>11</sup> vector genomes in a total volume of 0.3 mL injected into each eye on separate days within a close interval (no fewer than 6 days apart); in trials, the youngest patients were 4 years of age.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064585"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51064584"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F50889210"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Cataract (≤20%), conjunctival hyperemia (≤22%), increased intraocular pressure (≤15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Ophthalmic: Corneal thinning (≤7%), endophthalmitis (≤2%), eye disease (macular hole: ≤7%), eye irritation (≤5%), eye pain (≤5%), maculopathy (surface wrinkling: ≤5%), ophthalmic inflammation (≤5%), retinal changes (foveal thinning and loss of foveal function: ≤2%), retinal deposits (subretinal: ≤7%), retinal hemorrhage (≤2%), retinal pigment epithelium tear (≤10%), retinopathy (foveal dehiscence [separation of the retinal layers in the center of the macula]: ≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Ophthalmic: Retinal disturbance (chorioretinal atrophy)</p></div>
<div class="block coi drugH1Div" id="F50874747"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to voretigene neparvovec or any component of the formulation; ocular or periocular infection; active intraocular inflammation.</p></div>
<div class="block war drugH1Div" id="F51062982"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cataracts: Subretinal injection, especially vitrectomy surgery, may increase risk of cataract development or progression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endophthalmitis: May occur following intraocular surgical procedure or injection; use proper aseptic injection techniques. Monitor for signs or symptoms of infection or inflammation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure (IOP): Following subretinal injection, IOP may increase; monitor for IOP.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal abnormalities: Retinal abnormalities may occur during or after subretinal injection or vitrectomy, including macular holes, foveal thinning, loss of foveal function, foveal dehiscence, retinal hemorrhage, retinal tears, epiretinal membrane, and retinal detachment; monitor for macular abnormalities, retinal tears or detachment. Avoid administration in immediate vicinity of fovea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vision loss: Expansion of intraocular air bubble may lead to irreversible vision loss; avoid air travel, travel to high elevations, and scuba diving until air bubble has completely dissipated (may take 1 week or more following injection); verify air bubble dissipation through ophthalmic examination. Permanent decline in visual acuity may occur; monitor for visual disturbances.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878820"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use in infants is not recommended due to ongoing retinal cell proliferation, which may dilute or cause loss of drug. In trials, the youngest patients included were 4 years old.</p></div>
<div class="block foc drugH1Div" id="F50929309"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intraocular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luxturna: Voretigene neparvovec-rzyl 5 trillion VG/mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intraocular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luxturna: Voretigene neparvovec-rzyl 5 trillion VG/mL (0.5 mL)</p></div>
<div class="block geq drugH1Div" id="F50929307"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52909655"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Luxturna Intraocular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000000000000VG/ML (per 0.5 mL): $510,000.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56774951"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intraocular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luxturna: 5000000000000 VG/ML (1 ea)</p></div>
<div class="block adm drugH1Div" id="F51062968"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Subretinal: For subretinal injection only. Apply a topical broad spectrum microbiocide to the conjunctiva, cornea, and eyelids prior to surgery. Inject along the superior vascular arcade, at least 2 mm distal to the center of the fovea, avoiding direct contact with the retinal vasculature or areas of pathologic features (such as dense atrophy or intraretinal migration). Inject small amount of product slowly until an initial subretinal bleb is observed; inject remaining volume slowly until the total 0.3 mL is delivered. Refer to manufacturer's labeling for additional detailed information.</p>
<p style="text-indent:-2em;margin-left:2em;">Following injection, initiate supine head positioning immediately. Rest in a supine position as much as possible for the next 24 hours.</p></div>
<div class="block admp drugH1Div" id="F52614670"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: <b>For administration in surgical suite only by physician experienced in performing intraocular surgery.</b> Apply a topical broad spectrum microbiocide to the conjunctiva, cornea, and eyelids prior to surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">Subretinal injection: Attach sterile syringe to the provided extension tube (not to exceed 15.2 cm in length, 1.4 mm in diameter) and subretinal injection cannula; depress plunger slowly to 0.3 mL mark to prime tubing/cannula and eliminate any air bubbles. After appropriate preparation of the eye, inject along the superior vascular arcade, at least 2 mm distal to the center of the fovea, avoiding direct contact with the retinal vasculature or areas of pathologic features (such as dense atrophy or intraretinal migration). Inject small amount of product slowly until an initial subretinal bleb is observed; inject remaining volume slowly until the total 0.3 mL is delivered. Refer to manufacturer's labeling for additional detailed information.</p>
<p style="text-indent:-2em;margin-left:2em;">Following injection, initiate supine head positioning immediately. Rest in a supine position as much as possible for the next 24 hours.</p></div>
<div class="block use drugH1Div" id="F50874746"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Retinal dystrophy:</b> Treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients with viable retinal cells as determined by treating health care provider.</p></div>
<div class="block cyt drugH1Div" id="F50907441"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50907438"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F51062987"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F51062988"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if voretigene neparvovec is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F51062970"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Increase in intraocular pressure; retinal abnormalities (eg, macular holes, foveal thinning, loss of foveal function, foveal dehiscence, retinal hemorrhage, retinal tears, epiretinal membrane or retinal detachment) during and after injection; signs/symptoms of infection or inflammation; visual disturbance</p></div>
<div class="block pha drugH1Div" id="F51062986"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Voretigene neparvovec is an adeno-associated virus vector-based gene therapy that delivers a normal copy of the gene encoding human retinal pigment epithelial 65 kDa protein (RPE65) to retinal cells thus augmenting reduced or absent levels of biologically active RPE65. The RPE65 gene mutations lead to reduced or absent levels of RPE65 isomerohydrolase activity, blocking the visual cycle and ultimately impairing vision.</p></div>
<div class="block phk drugH1Div" id="F51062977"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Low</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Luxturna.1">
<a name="Luxturna.1"></a>Luxturna (voretigene neparvovec) [prescribing information]. Philadelphia, PA: Spark Therapeutics Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Luxturna.2">
<a name="Luxturna.2"></a>Luxturna (voretigene neparvovec) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 116161 Version 38.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
